Omalizumab induced Takotsubo syndrome : case report
| Autor: | Luis Bras-Rosario, I Aguiar-Ricardo, A Nunes-Ferreira, Ângela Roda |
|---|---|
| Přispěvatelé: | Repositório da Universidade de Lisboa |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Case Reports Omalizumab 030204 cardiovascular system & hematology Monoclonal antibody Coronary artery disease 03 medical and health sciences Basal (phylogenetics) 0302 clinical medicine Case report medicine 030212 general & internal medicine Adverse effect Takotsubo syndrome Left ventricular dysfunction business.industry medicine.disease Dermatology Monoclonal medicine.symptom Cardiology and Cardiovascular Medicine business Hyperkinesia medicine.drug |
| Zdroj: | Repositório Científico de Acesso Aberto de Portugal Repositório Científico de Acesso Aberto de Portugal (RCAAP) instacron:RCAAP European Heart Journal: Case Reports |
| Popis: | © The Author(s) 2019.The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Background: Omalizumab is a humanized monoclonal anti-immunoglobulin E antibody, approved for the treatment of spontaneous chronic urticaria, with high efficacy and an excellent safety profile. Although its adverse effects are rare, allergic reactions and cardiovascular events were previously described. Case summary: The authors describe the case of a 75-year-old woman, followed at the outpatient dermatology clinic due to spontaneous chronic urticaria, treated with omalizumab 300 mg every 4 weeks. After the 11th administration of omalizumab, the patient developed an episode of thoracalgia associated with electro- and echocardiographic abnormalities. Coronary angiogram excluded coronary artery disease, and left ventriculography demonstrated mid-apical akinesia and basal hyperkinesia, consistent with the Takotsubo syndrome (TS). Discussion: Takotsubo syndrome was already reported in association with other monoclonal antibodies. However, to our knowledge, this is the first case of TS following the administration of omalizumab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|